Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Transplant for MRD-Negative AML
NCT03515707Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2018
- Primary completion
- Apr 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous hematopoietic stem cells in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Probability of Relapse at 2 years. Planned start Jul 2018; status: withdrawn.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03515707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515707.